Status: Recruiting
LINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma
This is an open label, dose-seeking phase 1/2 study using escalating doses of LURBINECTEDIN administered intravenously with fixed doses of IPILIMUMAB and NIVOLUMAB administered intravenously.
Participants needed: 40
Trial details
Phase: Phase 1, Phase 2Age: 18-90Biological sex: AllType: InterventionalSponsor: ERLINDA M GORDONUpdated: Jul 5, 2024Locations: 1
Eligibility criteria
Male or Female ≥ 18 years of age [+12]
Subjects with untreated CNS metastases. Subjects are eligible if CNS metastases... [+20]